Report Cover

Global Hemoglobinopathies Market Research Report 2022


Hemoglobinopathies market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Hemoglobinopathies market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
    Blood Transfusion
    Iron Chelation Therapy
    Bone Marrow Transplant
    Others
Segment by Application
    Blood Testing
    Genetic Testing
    Pre-Implantation Genetic Diagnosis (PGD)
    Others
By Region
    North America
        United States
        Canada
    Europe
        Germany
        France
        UK
        Italy
        Russia
        Nordic Countries
        Rest of Europe
    Asia-Pacific
        China
        Japan
        South Korea
        Southeast Asia
        India
        Australia
        Rest of Asia
    Latin America
        Mexico
        Brazil
        Rest of Latin America
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE
        Rest of MEA
By Company
    Gamida Cell
    Alnylam Pharmaceuticals
    Sanofi
    Sangamo Therapeutics Inc.
    Global Blood Therapeutics
    Bluebird Bio
    Emmaus Life Sciences Inc.
    Prolong Pharmaceuticals
    Celgene Corporation
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Hemoglobinopathies Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
        1.2.2 Blood Transfusion
        1.2.3 Iron Chelation Therapy
        1.2.4 Bone Marrow Transplant
        1.2.5 Others
    1.3 Market by Application
        1.3.1 Global Hemoglobinopathies Market Share by Application: 2017 VS 2021 VS 2028
        1.3.2 Blood Testing
        1.3.3 Genetic Testing
        1.3.4 Pre-Implantation Genetic Diagnosis (PGD)
        1.3.5 Others
    1.4 Study Objectives
    1.5 Years Considered
2 Global Growth Trends
    2.1 Global Hemoglobinopathies Market Perspective (2017-2028)
    2.2 Hemoglobinopathies Growth Trends by Region
        2.2.1 Hemoglobinopathies Market Size by Region: 2017 VS 2021 VS 2028
        2.2.2 Hemoglobinopathies Historic Market Size by Region (2017-2022)
        2.2.3 Hemoglobinopathies Forecasted Market Size by Region (2023-2028)
    2.3 Hemoglobinopathies Market Dynamics
        2.3.1 Hemoglobinopathies Industry Trends
        2.3.2 Hemoglobinopathies Market Drivers
        2.3.3 Hemoglobinopathies Market Challenges
        2.3.4 Hemoglobinopathies Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Hemoglobinopathies Players by Revenue
        3.1.1 Global Top Hemoglobinopathies Players by Revenue (2017-2022)
        3.1.2 Global Hemoglobinopathies Revenue Market Share by Players (2017-2022)
    3.2 Global Hemoglobinopathies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Hemoglobinopathies Revenue
    3.4 Global Hemoglobinopathies Market Concentration Ratio
        3.4.1 Global Hemoglobinopathies Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Hemoglobinopathies Revenue in 2021
    3.5 Hemoglobinopathies Key Players Head office and Area Served
    3.6 Key Players Hemoglobinopathies Product Solution and Service
    3.7 Date of Enter into Hemoglobinopathies Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Hemoglobinopathies Breakdown Data by Type
    4.1 Global Hemoglobinopathies Historic Market Size by Type (2017-2022)
    4.2 Global Hemoglobinopathies Forecasted Market Size by Type (2023-2028)
5 Hemoglobinopathies Breakdown Data by Application
    5.1 Global Hemoglobinopathies Historic Market Size by Application (2017-2022)
    5.2 Global Hemoglobinopathies Forecasted Market Size by Application (2023-2028)
6 North America
    6.1 North America Hemoglobinopathies Market Size (2017-2028)
    6.2 North America Hemoglobinopathies Market Size by Country (2017-2022)
    6.3 North America Hemoglobinopathies Market Size by Country (2023-2028)
    6.4 United States
    6.5 Canada
7 Europe
    7.1 Europe Hemoglobinopathies Market Size (2017-2028)
    7.2 Europe Hemoglobinopathies Market Size by Country (2017-2022)
    7.3 Europe Hemoglobinopathies Market Size by Country (2023-2028)
    7.4 Germany
    7.5 France
    7.6 U.K.
    7.7 Italy
    7.8 Russia
    7.9 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Hemoglobinopathies Market Size (2017-2028)
    8.2 Asia-Pacific Hemoglobinopathies Market Size by Country (2017-2022)
    8.3 Asia-Pacific Hemoglobinopathies Market Size by Country (2023-2028)
    8.4 China
    8.5 Japan
    8.6 South Korea
    8.7 Southeast Asia
    8.8 India
    8.9 Australia
9 Latin America
    9.1 Latin America Hemoglobinopathies Market Size (2017-2028)
    9.2 Latin America Hemoglobinopathies Market Size by Country (2017-2022)
    9.3 Latin America Hemoglobinopathies Market Size by Country (2023-2028)
    9.4 Mexico
    9.5 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Hemoglobinopathies Market Size (2017-2028)
    10.2 Middle East & Africa Hemoglobinopathies Market Size by Country (2017-2022)
    10.3 Middle East & Africa Hemoglobinopathies Market Size by Country (2023-2028)
    10.4 Turkey
    10.5 Saudi Arabia
    10.6 UAE
11 Key Players Profiles
    11.1 Gamida Cell
        11.1.1 Gamida Cell Company Detail
        11.1.2 Gamida Cell Business Overview
        11.1.3 Gamida Cell Hemoglobinopathies Introduction
        11.1.4 Gamida Cell Revenue in Hemoglobinopathies Business (2017-2022)
        11.1.5 Gamida Cell Recent Development
    11.2 Alnylam Pharmaceuticals
        11.2.1 Alnylam Pharmaceuticals Company Detail
        11.2.2 Alnylam Pharmaceuticals Business Overview
        11.2.3 Alnylam Pharmaceuticals Hemoglobinopathies Introduction
        11.2.4 Alnylam Pharmaceuticals Revenue in Hemoglobinopathies Business (2017-2022)
        11.2.5 Alnylam Pharmaceuticals Recent Development
    11.3 Sanofi
        11.3.1 Sanofi Company Detail
        11.3.2 Sanofi Business Overview
        11.3.3 Sanofi Hemoglobinopathies Introduction
        11.3.4 Sanofi Revenue in Hemoglobinopathies Business (2017-2022)
        11.3.5 Sanofi Recent Development
    11.4 Sangamo Therapeutics Inc.
        11.4.1 Sangamo Therapeutics Inc. Company Detail
        11.4.2 Sangamo Therapeutics Inc. Business Overview
        11.4.3 Sangamo Therapeutics Inc. Hemoglobinopathies Introduction
        11.4.4 Sangamo Therapeutics Inc. Revenue in Hemoglobinopathies Business (2017-2022)
        11.4.5 Sangamo Therapeutics Inc. Recent Development
    11.5 Global Blood Therapeutics
        11.5.1 Global Blood Therapeutics Company Detail
        11.5.2 Global Blood Therapeutics Business Overview
        11.5.3 Global Blood Therapeutics Hemoglobinopathies Introduction
        11.5.4 Global Blood Therapeutics Revenue in Hemoglobinopathies Business (2017-2022)
        11.5.5 Global Blood Therapeutics Recent Development
    11.6 Bluebird Bio
        11.6.1 Bluebird Bio Company Detail
        11.6.2 Bluebird Bio Business Overview
        11.6.3 Bluebird Bio Hemoglobinopathies Introduction
        11.6.4 Bluebird Bio Revenue in Hemoglobinopathies Business (2017-2022)
        11.6.5 Bluebird Bio Recent Development
    11.7 Emmaus Life Sciences Inc.
        11.7.1 Emmaus Life Sciences Inc. Company Detail
        11.7.2 Emmaus Life Sciences Inc. Business Overview
        11.7.3 Emmaus Life Sciences Inc. Hemoglobinopathies Introduction
        11.7.4 Emmaus Life Sciences Inc. Revenue in Hemoglobinopathies Business (2017-2022)
        11.7.5 Emmaus Life Sciences Inc. Recent Development
    11.8 Prolong Pharmaceuticals
        11.8.1 Prolong Pharmaceuticals Company Detail
        11.8.2 Prolong Pharmaceuticals Business Overview
        11.8.3 Prolong Pharmaceuticals Hemoglobinopathies Introduction
        11.8.4 Prolong Pharmaceuticals Revenue in Hemoglobinopathies Business (2017-2022)
        11.8.5 Prolong Pharmaceuticals Recent Development
    11.9 Celgene Corporation
        11.9.1 Celgene Corporation Company Detail
        11.9.2 Celgene Corporation Business Overview
        11.9.3 Celgene Corporation Hemoglobinopathies Introduction
        11.9.4 Celgene Corporation Revenue in Hemoglobinopathies Business (2017-2022)
        11.9.5 Celgene Corporation Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details

List of Tables Table 1. Global Hemoglobinopathies Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028 Table 2. Key Players of Blood Transfusion Table 3. Key Players of Iron Chelation Therapy Table 4. Key Players of Bone Marrow Transplant Table 5. Key Players of Others Table 6. Global Hemoglobinopathies Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028 Table 7. Global Hemoglobinopathies Market Size by Region (US$ Million): 2017 VS 2021 VS 2028 Table 8. Global Hemoglobinopathies Market Size by Region (2017-2022) & (US$ Million) Table 9. Global Hemoglobinopathies Market Share by Region (2017-2022) Table 10. Global Hemoglobinopathies Forecasted Market Size by Region (2023-2028) & (US$ Million) Table 11. Global Hemoglobinopathies Market Share by Region (2023-2028) Table 12. Hemoglobinopathies Market Trends Table 13. Hemoglobinopathies Market Drivers Table 14. Hemoglobinopathies Market Challenges Table 15. Hemoglobinopathies Market Restraints Table 16. Global Hemoglobinopathies Revenue by Players (2017-2022) & (US$ Million) Table 17. Global Hemoglobinopathies Market Share by Players (2017-2022) Table 18. Global Top Hemoglobinopathies Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hemoglobinopathies as of 2021) Table 19. Ranking of Global Top Hemoglobinopathies Companies by Revenue (US$ Million) in 2021 Table 20. Global 5 Largest Players Market Share by Hemoglobinopathies Revenue (CR5 and HHI) & (2017-2022) Table 21. Key Players Headquarters and Area Served Table 22. Key Players Hemoglobinopathies Product Solution and Service Table 23. Date of Enter into Hemoglobinopathies Market Table 24. Mergers & Acquisitions, Expansion Plans Table 25. Global Hemoglobinopathies Market Size by Type (2017-2022) & (US$ Million) Table 26. Global Hemoglobinopathies Revenue Market Share by Type (2017-2022) Table 27. Global Hemoglobinopathies Forecasted Market Size by Type (2023-2028) & (US$ Million) Table 28. Global Hemoglobinopathies Revenue Market Share by Type (2023-2028) Table 29. Global Hemoglobinopathies Market Size by Application (2017-2022) & (US$ Million) Table 30. Global Hemoglobinopathies Revenue Market Share by Application (2017-2022) Table 31. Global Hemoglobinopathies Forecasted Market Size by Application (2023-2028) & (US$ Million) Table 32. Global Hemoglobinopathies Revenue Market Share by Application (2023-2028) Table 33. North America Hemoglobinopathies Market Size by Country (2017-2022) & (US$ Million) Table 34. North America Hemoglobinopathies Market Size by Country (2023-2028) & (US$ Million) Table 35. Europe Hemoglobinopathies Market Size by Country (2017-2022) & (US$ Million) Table 36. Europe Hemoglobinopathies Market Size by Country (2023-2028) & (US$ Million) Table 37. Asia-Pacific Hemoglobinopathies Market Size by Region (2017-2022) & (US$ Million) Table 38. Asia-Pacific Hemoglobinopathies Market Size by Region (2023-2028) & (US$ Million) Table 39. Latin America Hemoglobinopathies Market Size by Country (2017-2022) & (US$ Million) Table 40. Latin America Hemoglobinopathies Market Size by Country (2023-2028) & (US$ Million) Table 41. Middle East & Africa Hemoglobinopathies Market Size by Country (2017-2022) & (US$ Million) Table 42. Middle East & Africa Hemoglobinopathies Market Size by Country (2023-2028) & (US$ Million) Table 43. Gamida Cell Company Detail Table 44. Gamida Cell Business Overview Table 45. Gamida Cell Hemoglobinopathies Product Table 46. Gamida Cell Revenue in Hemoglobinopathies Business (2017-2022) & (US$ Million) Table 47. Gamida Cell Recent Development Table 48. Alnylam Pharmaceuticals Company Detail Table 49. Alnylam Pharmaceuticals Business Overview Table 50. Alnylam Pharmaceuticals Hemoglobinopathies Product Table 51. Alnylam Pharmaceuticals Revenue in Hemoglobinopathies Business (2017-2022) & (US$ Million) Table 52. Alnylam Pharmaceuticals Recent Development Table 53. Sanofi Company Detail Table 54. Sanofi Business Overview Table 55. Sanofi Hemoglobinopathies Product Table 56. Sanofi Revenue in Hemoglobinopathies Business (2017-2022) & (US$ Million) Table 57. Sanofi Recent Development Table 58. Sangamo Therapeutics Inc. Company Detail Table 59. Sangamo Therapeutics Inc. Business Overview Table 60. Sangamo Therapeutics Inc. Hemoglobinopathies Product Table 61. Sangamo Therapeutics Inc. Revenue in Hemoglobinopathies Business (2017-2022) & (US$ Million) Table 62. Sangamo Therapeutics Inc. Recent Development Table 63. Global Blood Therapeutics Company Detail Table 64. Global Blood Therapeutics Business Overview Table 65. Global Blood Therapeutics Hemoglobinopathies Product Table 66. Global Blood Therapeutics Revenue in Hemoglobinopathies Business (2017-2022) & (US$ Million) Table 67. Global Blood Therapeutics Recent Development Table 68. Bluebird Bio Company Detail Table 69. Bluebird Bio Business Overview Table 70. Bluebird Bio Hemoglobinopathies Product Table 71. Bluebird Bio Revenue in Hemoglobinopathies Business (2017-2022) & (US$ Million) Table 72. Bluebird Bio Recent Development Table 73. Emmaus Life Sciences Inc. Company Detail Table 74. Emmaus Life Sciences Inc. Business Overview Table 75. Emmaus Life Sciences Inc. Hemoglobinopathies Product Table 76. Emmaus Life Sciences Inc. Revenue in Hemoglobinopathies Business (2017-2022) & (US$ Million) Table 77. Emmaus Life Sciences Inc. Recent Development Table 78. Prolong Pharmaceuticals Company Detail Table 79. Prolong Pharmaceuticals Business Overview Table 80. Prolong Pharmaceuticals Hemoglobinopathies Product Table 81. Prolong Pharmaceuticals Revenue in Hemoglobinopathies Business (2017-2022) & (US$ Million) Table 82. Prolong Pharmaceuticals Recent Development Table 83. Celgene Corporation Company Detail Table 84. Celgene Corporation Business Overview Table 85. Celgene Corporation Hemoglobinopathies Product Table 86. Celgene Corporation Revenue in Hemoglobinopathies Business (2017-2022) & (US$ Million) Table 87. Celgene Corporation Recent Development Table 88. Research Programs/Design for This Report Table 89. Key Data Information from Secondary Sources Table 90. Key Data Information from Primary Sources List of Figures Figure 1. Global Hemoglobinopathies Market Share by Type: 2021 VS 2028 Figure 2. Blood Transfusion Features Figure 3. Iron Chelation Therapy Features Figure 4. Bone Marrow Transplant Features Figure 5. Others Features Figure 6. Global Hemoglobinopathies Market Share by Application in 2021 & 2028 Figure 7. Blood Testing Case Studies Figure 8. Genetic Testing Case Studies Figure 9. Pre-Implantation Genetic Diagnosis (PGD) Case Studies Figure 10. Others Case Studies Figure 11. Hemoglobinopathies Report Years Considered Figure 12. Global Hemoglobinopathies Market Size (US$ Million), Year-over-Year: 2017-2028 Figure 13. Global Hemoglobinopathies Market Size, (US$ Million), 2017 VS 2021 VS 2028 Figure 14. Global Hemoglobinopathies Market Share by Region: 2021 VS 2028 Figure 15. Global Hemoglobinopathies Market Share by Players in 2021 Figure 16. Global Top Hemoglobinopathies Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hemoglobinopathies as of 2021) Figure 17. The Top 10 and 5 Players Market Share by Hemoglobinopathies Revenue in 2021 Figure 18. North America Hemoglobinopathies Market Size YoY Growth (2017-2028) & (US$ Million) Figure 19. North America Hemoglobinopathies Market Share by Country (2017-2028) Figure 20. United States Hemoglobinopathies Market Size YoY Growth (2017-2028) & (US$ Million) Figure 21. Canada Hemoglobinopathies Market Size YoY Growth (2017-2028) & (US$ Million) Figure 22. Europe Hemoglobinopathies Market Size YoY Growth (2017-2028) & (US$ Million) Figure 23. Europe Hemoglobinopathies Market Share by Country (2017-2028) Figure 24. Germany Hemoglobinopathies Market Size YoY Growth (2017-2028) & (US$ Million) Figure 25. France Hemoglobinopathies Market Size YoY Growth (2017-2028) & (US$ Million) Figure 26. U.K. Hemoglobinopathies Market Size YoY Growth (2017-2028) & (US$ Million) Figure 27. Italy Hemoglobinopathies Market Size YoY Growth (2017-2028) & (US$ Million) Figure 28. Russia Hemoglobinopathies Market Size YoY Growth (2017-2028) & (US$ Million) Figure 29. Nordic Countries Hemoglobinopathies Market Size YoY Growth (2017-2028) & (US$ Million) Figure 30. Asia-Pacific Hemoglobinopathies Market Size YoY Growth (2017-2028) & (US$ Million) Figure 31. Asia-Pacific Hemoglobinopathies Market Share by Region (2017-2028) Figure 32. China Hemoglobinopathies Market Size YoY Growth (2017-2028) & (US$ Million) Figure 33. Japan Hemoglobinopathies Market Size YoY Growth (2017-2028) & (US$ Million) Figure 34. South Korea Hemoglobinopathies Market Size YoY Growth (2017-2028) & (US$ Million) Figure 35. Southeast Asia Hemoglobinopathies Market Size YoY Growth (2017-2028) & (US$ Million) Figure 36. India Hemoglobinopathies Market Size YoY Growth (2017-2028) & (US$ Million) Figure 37. Australia Hemoglobinopathies Market Size YoY Growth (2017-2028) & (US$ Million) Figure 38. Latin America Hemoglobinopathies Market Size YoY Growth (2017-2028) & (US$ Million) Figure 39. Latin America Hemoglobinopathies Market Share by Country (2017-2028) Figure 40. Mexico Hemoglobinopathies Market Size YoY Growth (2017-2028) & (US$ Million) Figure 41. Brazil Hemoglobinopathies Market Size YoY Growth (2017-2028) & (US$ Million) Figure 42. Middle East & Africa Hemoglobinopathies Market Size YoY Growth (2017-2028) & (US$ Million) Figure 43. Middle East & Africa Hemoglobinopathies Market Share by Country (2017-2028) Figure 44. Turkey Hemoglobinopathies Market Size YoY Growth (2017-2028) & (US$ Million) Figure 45. Saudi Arabia Hemoglobinopathies Market Size YoY Growth (2017-2028) & (US$ Million) Figure 46. Gamida Cell Revenue Growth Rate in Hemoglobinopathies Business (2017-2022) Figure 47. Alnylam Pharmaceuticals Revenue Growth Rate in Hemoglobinopathies Business (2017-2022) Figure 48. Sanofi Revenue Growth Rate in Hemoglobinopathies Business (2017-2022) Figure 49. Sangamo Therapeutics Inc. Revenue Growth Rate in Hemoglobinopathies Business (2017-2022) Figure 50. Global Blood Therapeutics Revenue Growth Rate in Hemoglobinopathies Business (2017-2022) Figure 51. Bluebird Bio Revenue Growth Rate in Hemoglobinopathies Business (2017-2022) Figure 52. Emmaus Life Sciences Inc. Revenue Growth Rate in Hemoglobinopathies Business (2017-2022) Figure 53. Prolong Pharmaceuticals Revenue Growth Rate in Hemoglobinopathies Business (2017-2022) Figure 54. Celgene Corporation Revenue Growth Rate in Hemoglobinopathies Business (2017-2022) Figure 55. Bottom-up and Top-down Approaches for This Report Figure 56. Data Triangulation Figure 57. Key Executives Interviewed

This research study involved the extensive usage of both primary and secondary data sources.  The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. Top-down and bottom-up approaches are used to validate the global market size market and estimate the market size for manufacturers, regions segments, product segments and applications (end users). All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or other factors are not accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from QYResearch and presented in this report.
 

After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation, extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
 

Secondary Sources occupies Approximately 25% of Sources, such as press releases, annual reports, Non-Profit organizations, industry associations, governmental agencies and customs data, and so on; This research study involved the usage of widespread secondary sources; directories; databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), TRADING ECONOMICS, and avention; Investing News Network; statista; Federal Reserve Economic Data; annual reports; BIS Statistics; ICIS; company house documents; CAS(American Chemical Society); investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the Light Aircraft market. It was also used to obtain important information about the top players, market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives.
 

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers etc.
 

The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users (product buyers), and related key executives from various key companies and organizations operating in the global market.
 

Primary research was conducted to identify segmentation types, product price range, product applications, key players, raw materials supply and the downstream demand, industry status and outlook, and key market dynamics such as risks, influence factors, opportunities, market barriers, industry trends, and key player strategies.
 

Publisher: QY Research
Chat with us